Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 6/20 | 0.45 |
| ▸ | CNR2 | P34972 | 5/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NPR3 | P17342 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524415 | 0.90 | CNR2 (0.48) | PTK2CNR2BTKGSK3AGSK3B | |
| SCHEMBL15524302 | 0.89 | IGF1R (0.44) | CNR2IGF1RBTKKDM4EMAPT | |
| SCHEMBL15524532 | 0.83 | FLT4 (0.39) | PTK2FLT4MAPTCYP3A4CYP2C8 | |
| SCHEMBL15524522 | 0.82 | CCNA2 (0.51) | PTK2FLT4GSK3AGSK3B | |
| SCHEMBL15524110 | 0.82 | PTK2 (0.46) | PTK2FLT4 | |
| SCHEMBL15524495 | 0.81 | FLT4 (0.48) | PTK2CNR2FLT4GSK3AGSK3B | |
| SCHEMBL14577154 | 0.81 | PTK2 (0.52) | PTK2FLT4 | |
| SCHEMBL15524665 | 0.80 | GSK3A (0.40) | PTK2CNR2MAPTGSK3AGSK3B | |
| SCHEMBL14576729 | 0.79 | PTK2 (0.49) | PTK2FLT4 | |
| SCHEMBL15524831 | 0.79 | EGFR (0.46) | CNR2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20090068168-A1 | SUBSTITUTED AMINO ALCOHOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068168-A1 | SUBSTITUTED AMINO ALCOHOLS | GOT1, AADAT, ADH1A | PTK2 3451/4885CNR2 3404/4885FLT4 4643/4885 |
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | PTK2 240/4885CNR2 1834/4885FLT4 1/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | PTK2 260/4885CNR2 1810/4885FLT4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.